CL2021001509A1 - Derivados de xantina sustituida - Google Patents
Derivados de xantina sustituidaInfo
- Publication number
- CL2021001509A1 CL2021001509A1 CL2021001509A CL2021001509A CL2021001509A1 CL 2021001509 A1 CL2021001509 A1 CL 2021001509A1 CL 2021001509 A CL2021001509 A CL 2021001509A CL 2021001509 A CL2021001509 A CL 2021001509A CL 2021001509 A1 CL2021001509 A1 CL 2021001509A1
- Authority
- CL
- Chile
- Prior art keywords
- xanthine derivatives
- substituted xanthine
- substituted
- trpc5
- therapy
- Prior art date
Links
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 title 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 title 1
- 102000004310 Ion Channels Human genes 0.000 abstract 1
- 102000003621 TRPC5 Human genes 0.000 abstract 1
- 101150042815 TRPC5 gene Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a compuestos de la Fórmula I, un procedimiento para su fabricación, composiciones farmacéuticas que los contienen y su uso en terapia, particularmente en el tratamiento de afecciones que tienen una asociación con los canales iónicos que contienen TRPC5. R1, R2, R3, R4 y R5 tienen los significados dados en la descripción.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18212060 | 2018-12-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021001509A1 true CL2021001509A1 (es) | 2021-12-17 |
Family
ID=64665184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021001509A CL2021001509A1 (es) | 2018-12-12 | 2021-06-09 | Derivados de xantina sustituida |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11198696B2 (es) |
| EP (1) | EP3894410B1 (es) |
| JP (1) | JP7502299B2 (es) |
| KR (1) | KR20210102955A (es) |
| CN (1) | CN113166151B (es) |
| AU (1) | AU2019396499A1 (es) |
| BR (1) | BR112021008316A2 (es) |
| CA (1) | CA3119229A1 (es) |
| CL (1) | CL2021001509A1 (es) |
| DK (1) | DK3894410T3 (es) |
| EA (1) | EA202191588A1 (es) |
| ES (1) | ES2964630T3 (es) |
| HU (1) | HUE064908T2 (es) |
| IL (1) | IL283768B2 (es) |
| MX (1) | MX2021007019A (es) |
| PL (1) | PL3894410T3 (es) |
| TW (1) | TWI825243B (es) |
| WO (1) | WO2020120450A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021007019A (es) * | 2018-12-12 | 2021-09-10 | Boehringer Ingelheim Int | Derivados de xantina sustituida. |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2970303T1 (sl) | 2013-03-15 | 2017-08-31 | Hydra Biosciences, Inc. | Substituirani ksantini in njihove metode uporabe |
| EP3180340B1 (en) | 2014-08-11 | 2018-10-10 | Hydra Biosciences, Inc. | Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives |
| GB201702160D0 (en) | 2017-02-09 | 2017-03-29 | Univ Leeds Innovations Ltd | Inhibitors for use in therapy |
| CA3066922A1 (en) * | 2017-07-11 | 2019-01-17 | Boehringer Ingelheim International Gmbh | Novel substituted xanthine derivatives |
| MX2021007019A (es) * | 2018-12-12 | 2021-09-10 | Boehringer Ingelheim Int | Derivados de xantina sustituida. |
-
2019
- 2019-12-10 MX MX2021007019A patent/MX2021007019A/es unknown
- 2019-12-10 CA CA3119229A patent/CA3119229A1/en active Pending
- 2019-12-10 EA EA202191588A patent/EA202191588A1/ru unknown
- 2019-12-10 AU AU2019396499A patent/AU2019396499A1/en active Pending
- 2019-12-10 PL PL19820718.5T patent/PL3894410T3/pl unknown
- 2019-12-10 DK DK19820718.5T patent/DK3894410T3/da active
- 2019-12-10 HU HUE19820718A patent/HUE064908T2/hu unknown
- 2019-12-10 BR BR112021008316-2A patent/BR112021008316A2/pt unknown
- 2019-12-10 CN CN201980081737.1A patent/CN113166151B/zh active Active
- 2019-12-10 JP JP2021533340A patent/JP7502299B2/ja active Active
- 2019-12-10 KR KR1020217021875A patent/KR20210102955A/ko unknown
- 2019-12-10 EP EP19820718.5A patent/EP3894410B1/en active Active
- 2019-12-10 WO PCT/EP2019/084375 patent/WO2020120450A1/en unknown
- 2019-12-10 IL IL283768A patent/IL283768B2/en unknown
- 2019-12-10 ES ES19820718T patent/ES2964630T3/es active Active
- 2019-12-11 US US16/710,887 patent/US11198696B2/en active Active
- 2019-12-12 TW TW108145593A patent/TWI825243B/zh active
-
2021
- 2021-06-09 CL CL2021001509A patent/CL2021001509A1/es unknown
- 2021-11-10 US US17/523,316 patent/US20220177479A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL283768B2 (en) | 2024-05-01 |
| BR112021008316A2 (pt) | 2021-08-03 |
| US11198696B2 (en) | 2021-12-14 |
| US20220177479A1 (en) | 2022-06-09 |
| US20200190093A1 (en) | 2020-06-18 |
| CA3119229A1 (en) | 2020-06-18 |
| JP2022512373A (ja) | 2022-02-03 |
| PL3894410T3 (pl) | 2024-03-18 |
| EA202191588A1 (ru) | 2021-10-18 |
| TWI825243B (zh) | 2023-12-11 |
| WO2020120450A1 (en) | 2020-06-18 |
| AU2019396499A1 (en) | 2021-05-27 |
| JP7502299B2 (ja) | 2024-06-18 |
| HUE064908T2 (hu) | 2024-04-28 |
| EP3894410A1 (en) | 2021-10-20 |
| IL283768A (en) | 2021-07-29 |
| ES2964630T3 (es) | 2024-04-08 |
| MX2021007019A (es) | 2021-09-10 |
| IL283768B1 (en) | 2024-01-01 |
| TW202039495A (zh) | 2020-11-01 |
| KR20210102955A (ko) | 2021-08-20 |
| EP3894410B1 (en) | 2023-10-11 |
| CN113166151B (zh) | 2023-12-01 |
| DK3894410T3 (da) | 2023-11-27 |
| CN113166151A (zh) | 2021-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020000075A1 (es) | Carboxamidas como moduladores de los canales de sodio. | |
| CL2018003701A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| CL2018002410A1 (es) | Inhibidores de mcl-1 y métodos de uso de los mismos | |
| CL2019001664A1 (es) | Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2 y métodos de uso de los mismos. | |
| GEP20237506B (en) | Pcsk9 antagonist compounds | |
| CO2022001453A2 (es) | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2 | |
| SV2018005663A (es) | Compuestos de imidazo [4,5-c] quinolin-2-ona y su uso en el tratamiento del cancer | |
| SV2018005778A (es) | Derivados aromaticos de sulfonamida | |
| SV2018005687A (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer | |
| BR112018005497A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| CR20170116A (es) | Compuestos que inhiben la proteina mcl-1 | |
| BR112016028288A2 (pt) | ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto? | |
| BR112017002053A2 (pt) | composto de acordo com a fórmula (i), composição farmacêutica, e usos de um composto | |
| SV2018005680A (es) | Compuestos de imidazo [4,5-c] quinolin- 2-ona y su uso en el tratamiento del cancer | |
| CY1123263T1 (el) | Πολυκυκλικες ενωσεις ως αναστολεις κινασης τυροσινης bruton | |
| DOP2021000017A (es) | Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos | |
| BR112017009012A2 (pt) | derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso | |
| CL2020001062A1 (es) | Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos. | |
| CO2019015102A2 (es) | Nuevos derivados de xantina sustituidos | |
| CO2021006480A2 (es) | Inhibidores de rip1 | |
| CL2019002480A1 (es) | Derivados de pirazol como inhibidores de bromodominio. | |
| CL2021001509A1 (es) | Derivados de xantina sustituida | |
| MX2020004842A (es) | Compuestos heterociclicos antiinfecciosos y sus usos. | |
| CL2018002010A1 (es) | Derivados de indano y su uso en terapias. | |
| CL2021003228A1 (es) | Compuestos tricíclicos y su uso |